American Diabetes Association
Browse

Effect of Hyperketonemia on Myocardial Function in Patients with Heart Failure and Type 2 Diabetes

figure
posted on 2024-10-24, 14:56 authored by Carolina Solis-Herrera, Yuejuan Qin, Henri Honka, Eugenio Cersosimo, Curtis Triplitt, Sivaram Neppala, Jemena Rajan, Francisca M. Acosta, Alexander J. Moody, Patricio Iozzo, Peter Fox, Geoffrey Clarke, Ralph A. DeFronzo

ABSTRACT We examined the effect of increased plasma ketones on left ventricular (LV) function, myocardial glucose uptake (MGU), and myocardial blood flow (MBF) in type 2 diabetes (T2DM) patients with heart failure (HF). Three groups (I,II,III) of T2DM (12 per group) with LV ejection fraction £50% received incremental infusions of β-OH-B for 3-6 hours to raise plasma b-OH-B concentration throughout the physiologic (Groups I and II) and pharmacologic (Group III) range. Cardiac MRI was performed at baseline and after each b-OH-B infusion to provide measures of cardiac function. On a separate day, Group II also received NaHCO3 infusion, thus serving as their own control for time, volume, and pH. Additionally, Group II underwent positron emission tomography study with 18F-fluoro-2-deoxyglucose to examine effect of hyperketonemia on MGU. Groups I, II, III achieved plasma b-OH-B levels of 0.7±0.3, 1.6±0.2, 3.2±0.2 mmol/L, respectively. Cardiac output, LVEF, and stroke volume increased significantly during b-OH-B infusion in Groups II (CO, 4.54 to 5.30; EF, 39.9 to 43.8; SV, 70.3 to 80.0) and III (CO, 5.93 to 7.16; EF, 41.1 to 47.5; SV, 89.0 to 108.4) and did not change with NaHCO3 infusion in Group II. The increase in LVEF was greatest in Group III (p<0.001 vs Group II). MGU and MBF were not altered by β-OH-B. In T2DM patients with LVEF£50%, increased plasma b-OH-B significantly increased LV function dose-dependently. Since MGU did not change, the myocardial benefit of b-OH-B resulted from providing an additional fuel for the heart without inhibiting MGU. HIGHLIGHTS · SGLT2 inhibitor therapy is associated with an increase in plasma ketone concentration · We examined in type 2 diabetes patients with HFrEF the effect of b-OH-B infusion, spanning the physiologic and pharmacologic range of plasma b-OH-B concentrations (0.7, 1.6, and 3.2 mmol/L), on myocardial function (MRI), myocardial blood flow (PET/H215O), and myocardial glucose uptake (PET/18F—DOG) · b-OH-B caused a dose-response increase in left ventricular ejection fraction and myocardial blood flow without altering myocardial glucose uptake These results suggest that the SLGT2i-induced increase in plasma ketone concentration may contribute to its beneficial effects on myocardial function

Funding

Max and Minnie Tomerlin Voelcker Fund

MERCK Pharmaceuticals

NIDDK/NIH R01DK24092

History

Usage metrics

    Diabetes

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC